599 related articles for article (PubMed ID: 16167412)
1. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
2. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Saini R; Tutrone WD; Weinberg JM
Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
[TBL] [Abstract][Full Text] [Related]
3. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
Tutrone WD; Saini R; Weinberg JM
IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
[TBL] [Abstract][Full Text] [Related]
4. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
7. New biologic therapies for psoriatic disease.
Bohjanen KA; Prawer SE
Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
Langley RG; Gupta AK; Cherman AM; Inniss KA
J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
[TBL] [Abstract][Full Text] [Related]
9. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
10. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
12. Update on the mechanisms and efficacy of biological therapies for psoriasis.
Koo J; Khera P
J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
[TBL] [Abstract][Full Text] [Related]
13. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
Graves JE; Nunley K; Heffernan MP
J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
[TBL] [Abstract][Full Text] [Related]
14. Biologic therapies for psoriasis. A systematic review.
Boehncke WH; Prinz J; Gottlieb AB
J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Tutrone WD
Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
[TBL] [Abstract][Full Text] [Related]
17. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
18. Immunobiologics in the treatment of psoriasis.
Chong BF; Wong HK
Clin Immunol; 2007 May; 123(2):129-38. PubMed ID: 17317321
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
